News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Real-time Estimate Cboe BZX Other stock markets 03:35:30 2024-05-23 pm EDT			5-day change	1st Jan Change
41.6 ^USD	-1.74%		-5.71%	-18.94%

06:31pm	Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment	MT
May. 22	Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million	RE

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment	12:31pm	MT
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting	07:00am	BU
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million	May. 22	RE
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab	May. 22	AQ
Bristol-Myers Squibb Announces Strategies to Improve Access to Medicines	May. 22	MT
Bristol Myers: 10-year strategy for poor countries	May. 22	CF
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries	May. 22	BU
Bristol-Myers Squibb Invests in NeoPhore	May. 22	MT
Hawaii court orders drug companies to pay $916 million in Plavix blood thinner lawsuit	May. 22	AQ
Bristol Myers: national schizophrenia campaign	May. 21	CF
Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign	May. 21	BU
Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab	May. 21	MT
Bristol Myers: deadline set for subcutaneous Opdivo	May. 21	CF
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	May. 21	BU
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis	May. 16	BU
Everlasting momentum	May. 16
Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma	May. 16	DJ
Bristol Myers Squibb : Transcript	May. 16	PU
Bristol-Myers Squibb Gets FDA Accelerated Approval for Breyanzi for Follicular Lymphoma	May. 16	MT
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma	May. 15	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST